The women were left with intense pain and fears of the development of new tumors caused by BioZorb after undergoing breast cancer surgery.
Ruling comes as more than 80 other BioZorb marker lawsuits are currently being pursued by breast cancer survivors left with painful and disfiguring injuries.
Doctors are being urged not to implant recalled BioZorb tissue markers in any new patients, and to closely monitor those who have received the implants.
Although a BioZorb recall has been issued for all versions of the breast tissue marker, Hologic is asking the court to throw out claims alleging injuries were caused by design defects.
Lawsuit comes days after FDA announced a BioZorb marker recall, indicating the implants are failing to properly be absorbed in women's bodies.
Manufacturer will remove all remaining BioZorb Markers from the market, following adverse events and lawsuits filed by women who experienced problems with the breast tissue implant.
Following pretrial motions for summary judgement, plaintiffs have filed a request to amend their BioZorb implant lawsuit, adding additional details in support of their design defect and failure to warn claims.
Four lawsuits over BioZorb Marker will be selected for early bellwether trials, to help gauge how juries may respond to evidence that the tissue marker caused painful complications.
Each of the women experienced severe complications from the BioZorb implant, after the radiographic marker failed to dissolve, migrated or fractured
Five different women joined together to file the lawsuit against BioZorb manufacturer, alleging that the recalled breast tissue markers failed to absorb, fractured or failed, causing painful injuries
